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Abstract
Parkinson’s disease (PD) is a neurologic disorder resulting from the loss of dopaminergic neurons in the brain.
Two lines of evidence suggest that the protein α-synuclein plays a role in the pathogenesis of PD: Fibrillar
α-synuclein is a major component of Lewy bodies in diseased neurons, and two mutations in α-synuclein are
linked to early-onset disease. Accordingly, the fibrillization of α-synuclein is proposed to contribute to neu-
rodegeneration in PD. In this report, we provide evidence that oligomeric intermediates of the α-synuclein fib-
rillization pathway, termed protofibrils, might be neurotoxic. Analyses of protofibrillar α-synuclein by atomic
force microscopy and electron microscopy indicate that the oligomers consist of spheres, chains, and rings.
α-Synuclein protofibrils permeabilize synthetic vesicles and form pore-like assemblies on the surface of brain-
derived vesicles. Dopamine reacts with α-synuclein to form a covalent adduct that slows the conversion of
protofibrils to fibrils. This finding suggests that cytosolic dopamine in dopaminergic neurons promotes the accu-
mulation of toxic α-synuclein protofibrils, which might explain why these neurons are most vulnerable to degen-
eration in PD. Finally, we note that aggregation of α-synuclein likely occurs via different mechanisms in the cell
versus the test tube. For example, the binding of α-synuclein to cellular membranes might influence its self-
assembly. To address this point, we have developed a yeast model that might enable the selection of random
α-synuclein mutants with different membrane-binding affinities. These variants might be useful to test whether
membrane binding by α-synuclein is necessary for neurodegeneration in transgenic animal models of PD.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative
disorder that affects approx 0.2% of the population
(Dunnett and Bjorklund, 1999; Dawson and Dawson,
2002). The symptoms, which include difficulty ini-
tiating movements, resting tremor, and rigidity,
result from the loss of dopaminergic neurons from
the substantia nigra (Pollanen et al., 1993; Forno,
1996; Dunnett and Bjorklund, 1999). The pathogenic
mechanisms leading to this degeneration of nigral
neurons are thought to involve mitochondrial
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impairment and oxidative stress (Orth and Schapira,
2002; Sherer et al., 2002). In addition, a neuropatho-
logical hallmark of PD is the presence in some sur-
viving neurons of cytosolic inclusions named Lewy
bodies (Takahashi and Wakabayashi, 2001).
Several key observations have led to the hypo-
thesis that the protein α-synuclein plays a role in
the pathogenesis of PD. Not only do Lewy bodies
consist primarily of fibrillar α-synuclein (Spillantini
et al., 1997, 1998; Wakabayashi et al., 1997; Arima
et al., 1998; Baba et al., 1998), but two mutations in
α-synuclein, A53T (Polymeropoulos et al., 1997) and
A30P (Kruger et al., 1998), have also been linked to
rare, early-onset forms of the disease. In addition,
the production of human α-synuclein in transgenic
mice (Masliah et al., 2000), rats (Kirik et al., 2002), or
flies (Feany and Bender, 2000) leads to a Parkinson-
ian phenotype, including the degeneration of
dopaminergic neurons, the presence of α-synuclein-
containing inclusions, and the onset of motor deficits.
Finally, the chronic exposure of rats to rotenone, a
mitochondrial complex I inhibitor, reproduces key
features of PD, including cytoplasmic, fibrillar inclu-
sions enriched with α-synuclein (Betarbet et al., 2000;
Sherer et al., 2003).
α-Synuclein is a small (14-kDa) cytosolic protein
that is abundant in presynaptic nerve terminals in
the brain (Maroteaux et al., 1988; Jakes et al., 1994;
Iwai et al., 1995; Clayton and George, 1999). Even in
benign buffer, the protein has a primarily random-
coil secondary structure and therefore, is referred
to as natively unfolded (Weinreb et al., 1996). The
N-terminal region of α-synuclein contains six
imperfect repeats of the amino acid sequence
KTK(E/Q)GV, which is similar to the characteristic
repeats of exchangeable apolipoproteins. The repeat
region of α-synuclein is predicted to adopt an amphi-
pathic α-helical structure upon the reversible asso-
ciation of the protein with synthetic vesicles or
membranes (Davidson et al., 1998; Perrin et al., 2000;
Bussell and Eliezer, 2003; Chandra et al., 2003).
Wild-type (WT) α-synuclein and the two PD
mutants, A53T and A30P, form fibrils in vitro that
are similar to the fibrils extracted from Lewy bodies
(Conway et al., 1998; El-Agnaf et al., 1998; Hashimoto
et al., 1998; Giasson et al., 1999; Narhi et al., 1999).
However, whereas A53T forms fibrils more rapidly
than WT α-synuclein, A30P forms fibrils less rapidly
than WT α-synuclein (Conway et al., 2000). In con-
trast, both A53T and A30Pform prefibrillar oligomers
(protofibrils) more rapidly than WT α-synuclein
(Conway et al., 2000; Li et al., 2001, 2002). These
results suggest that the early-onset disease associ-
ated with A53T and A30P is attributable not to accel-
erated α-synuclein fibrillization but, rather, to
accelerated protofibril formation. Consistent with
this hypothesis, at least two neuropathological obser-
vations suggest an imperfect correlation between
Lewy bodies and disease. First, dopaminergic neu-
rons of PD patients that contain Lewy bodies appear
to be healthier than adjacent neurons (Tompkins and
Hill, 1997). Second, Lewy bodies have been observed
in postmortem brain samples from elderly individ-
uals who were asymptomatic during their lifetime
(van Duinen et al., 1999). From all of these observa-
tions, we infer that α-synuclein protofibrils (rather
than fibrils) might be the toxic species underlying
PD pathogenesis.
An important goal of current research is to
provide evidence that supports a link between
α-synuclein protofibrils and PD. To this end, we
have attempted to identify toxic properties (e.g.,
membrane permeabilization) specifically associated
with protofibrillar but not monomeric or fibrillar
α-synuclein. In addition, we have screened small-
molecule libraries to identify compounds that sta-
bilize protofibrils by preventing their conversion to
mature fibrils. These compounds might then be used
in studies of α-synuclein-transgenic flies or mice to
test whether an increased accumulation of protofib-
rils in these transgenic animals produces a more
severe form of the disease. Finally, we have devel-
oped a yeast model that might enable the isolation
of random, unnatural variants of α-synuclein
with different propensities to bind to biological
membranes. These mutants might be useful to
test whether membrane binding is essential for
the nucleation event(s) leading to the formation of
α-synuclein protofibrils.
α-Synuclein Protofibrils Form
β-Sheet-Rich Rings and Can
Permeabilize Membranes
To begin to address why protofibrillar
α-synuclein might be neurotoxic, we compared the
structural and functional properties of the monomer
and protofibrils. The two forms of the protein were
isolated by gel filtration and analyzed by far-UV
circular dichroism (CD) and atomic force microscopy
(AFM) (Volles et al., 2001). The monomer, which
eluted in the included fraction from the gel-filtration
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column, exhibited a CD spectrum characteristic of a
primarily random-coil secondary structure.
Monomeric α-synuclein produced no significant
signal when analyzed by AFM, as predicted for a
small, natively unfolded protein. In contrast, the
protofibrils, which eluted in the void-volume frac-
tion from the gel-filtration column, exhibited a CD
spectrum characteristic of a primarily β-sheet sec-
ondary structure. In addition, the protofibrils were
detected as spheres with a height of 3–4 nm when
analyzed by AFM.
To understand how the formation of α-synuclein
spheres is related to other steps on the fibrillization
pathway, we carried out further analyses by AFM
and electron microscopy (EM). In some AFM images
(Conway et al., 2000), we observed that spheres
anneal in a linear fashion to form chains. As one
possibility, these chains might undergo winding
interactions to form rigid fibrils, via a mechanism
similar to that described for the fibrillization of the
amyloid-β peptide associated with Alzheimer’s
disease (Harper et al., 1997a, 1997b; Walsh et al.,
1997). In addition, we observed rings, or annular
protofibrils, which might result from the annealing
of spheres in circular fashion or from the circular-
ization of the protofibrillar chains (Fig. 1A,B). Rings
derived from WT α-synuclein, A53T, and A30P have
a diameter of 32–180, 10, or 55 nm, respectively (Ding
et al., 2002). In addition, ring-like species were
observed by EM analysis of α-synuclein from the
void-volume fraction (Lashuel et al., 2002). Single-
particle analysis enabled us to divide the rings into
groups of related structures. For each group, a rep-
resentative class-average structure was determined
(Fig. 1C). The diameter of the rings observed by EM
was 10–12 nm (A53T) or 8–24 nm (A30P).
Several groups have shown that monomeric
α-synuclein binds reversibly to synthetic vesicles
(Davidson et al., 1998; Jo et al., 2000; Perrin et al.,
2000; Eliezer et al., 2001). Given this information,
and because the structure of the α-synuclein ring
was suggestive of a pore, we examined whether
the annular protofibrils could bind and permeabi-
lize lipid membranes. Vesicles were purified from
the microsomal fraction of a rat brain lysate, incu-
bated with monomeric or protofibrillar α-synuclein,
and analyzed by AFM (Ding et al., 2002). Vesicles
treated with the protofibrils contained pore-like
structures with a diameter of 18–28 nm (Fig. 2A). In
contrast, such structures were not associated with
vesicles treated with the monomer. To address
whether the protofibrils permeabilize membranes,
acidic synthetic vesicles were loaded with the dye
Fura-2 and treated with monomeric or protofibril-
lar α-synuclein in a buffer that contained calcium
(Volles et al., 2001). In this assay, an increase in flu-
orescence indicates that a complex has formed
between the calcium ions and Fura-2 because of the
permeabilization of the vesicles. Incubation of the
Fura-2-loaded vesicles with α-synuclein protofibrils
led to a substantial increase in fluorescence, whereas
no fluorescence increase was observed compared to
the buffer control upon mixing the vesicles with
monomeric or fibrillar α-synuclein (Fig. 2B; not
shown). From these results, we concluded that
α-synuclein protofibrils, but not monomer or fibrils,
permeabilize lipid membranes. This membrane
permeabilization activity could potentially account
for the proposed toxicity of α-synuclein protofibrils
in PD.
Catecholamines Inhibit α-Synuclein
Fibrillization but Promote
Accumulation of Protofibrils
A current goal is to design in vivo experiments
to address whether the toxic protofibril hypothe-
sis accounts for the pathogenesis of PD. We have
Fig. 1.α-Synuclein protofibrils consist of spheres and rings.
(A) Schematic diagram depicting a possible route for the con-
version of spherical α-synuclein protofibrils to annular
protofibrils (rings). (B) AFM image (800 × 800 nm), showing
rings from an equimolar mixture of WT α-synuclein and A53T
(200 µM total). (C) Example of a class-average structure of an
α-synuclein ring, calculated from single-particle analysis of
A53T protofibrils imaged by negative-staining EM.
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considered two complementary strategies. First, one
might identify a small molecule that binds specifi-
cally to α-synuclein protofibrils and stabilizes them
by preventing their conversion to mature fibrils.
Second, one might generate random, unnatural vari-
ants of α-synuclein that accumulate as protofibrils
but do not form fibrils. If the toxic protofibril hypoth-
esis were correct, then an α synuclein-transgenic
animal treated with a drug that stabilizes protofib-
rils should develop a more severe Parkinsonian phe-
notype than an untreated control. Similarly, an
α-synuclein-transgenic animal that produces high
levels of a random mutant that forms protofibrils
but not fibrils should develop a more pronounced
form of the disease.
To identify small molecules that inhibit
α-synuclein fibrillization, we screened a small-
molecule library using the thioflavin-T assay
(Conway et al., 2001). Because thioflavin T binds to
mature fibrils, hits identified by this screen are
expected to inhibit fibrillization by one of two
mechanisms: (1) They might prevent the early
assembly of protofibrils from monomeric α-synuclein,
or (2) they might prevent the subsequent conver-
sion of protofibrils to fibrils. These possibilities are
distinguishable by quantifying the void-volume
oligomer in each sample via gel filtration, in par-
allel with the thioflavin-T measurements.
We screened 160 compounds from the LOPAC
library (Research Biochemicals, Inc./Sigma). Of
these, 15 inhibited α-synuclein fibrillization over a
3-d assay period. Remarkably, 14 of these hits were
catecholamines, including dopamine, L-DOPA,
epinephrine, and norepinephrine (Fig. 3A). The
catechol moiety was essential for inhibition, as
molecules in which either catechol hydroxyl group
had been modified had no effect on fibrillization
(Fig. 3B). In addition, the inhibitory activity of the
catecholamines was suppressed by antioxidants such
as sodium metabisulfite or desferrioxamine
combined with N-acetyl-cysteine (not shown). In
parallel experiments, samples of α-synuclein incu-
bated in the absence or presence of dopamine or
L-DOPA were analyzed by gel filtration. After 3 d,
a broad peak of absorbance at 276 nm (A276), which
included both void-volume and early included-
volume fractions, was associated with the samples
treated with either catecholamine but not with
the untreated protein. Western blot analysis of
α-synuclein treated with dopamine indicated that a
ladder of α-synuclein-immunoreactive bands
appeared and became progressively more intense
during the incubation (Fig. 4A). A smear at the top
of this ladder was similar to that reported for
protofibrillar α-synuclein in earlier studies (Volles
et al., 2001; Ding et al., 2002). From these results, it
was inferred that the inhibition of α-synuclein fibril-
lization by catecholamines leads to the accumula-
tion of a mixture of oligomers, some of which
correspond to the protofibrils observed previously.
We also determined that the A276 signal corre-
sponding to monomeric α-synuclein increased in the
samples treated with either catecholamine during
the course of the incubation. In addition, monomeric
Fig. 2. α-Synuclein protofibrils bind and permeabilize lipid vesicles. (A) AFM image (200 × 200 nm) showing
membrane-bound, ring-like structures formed by mixing protofibrillar A53T with brain-derived vesicles. (B) Graph
showing the increase in fluorescence with time upon incubating Fura-2-loaded, synthetic vesicles in a calcium buffer
in the absence or presence of α-synuclein monomer (26 µM) or protofibrils (4.2 µM). Only the protofibrils produce
a substantial increase in fluorescence, which indicates membrane permeabilization.
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α-synuclein treated with dopamine and then puri-
fied by gel filtration exhibited a fluorescence emis-
sion (λmax = 468 nm) when excited with light at a
wavelength of 360 nm. The untreated monomer did
not exhibit this fluorescence emission. From these
observations, we considered that α-synuclein might
be modified by oxidized dopamine. To address this
hypothesis, samples of α-synuclein were incubated
for various times in the presence of [3H]dopamine
and analyzed by gel filtration. The eluted fractions
were monitored by measuring A276 and by scintilla-
tion counting. After a 5-min incubation, a significant
level of radioactivity was associated with monomeric
α-synuclein (Fig. 4B). After a longer incubation
(11 d), a much higher level of radioactivity was asso-
ciated with both the monomer and the oligomer
(Fig. 4B). Moreover, the amount of radioactivity asso-
ciated with the purified monomer was not affected
by boiling the sample prior to gel filtration. There-
fore, it was concluded that α-synuclein is modified
by dopamine to form a covalent adduct.
Next, we hypothesized that the inhibition of
α-synuclein fibrillization by dopamine might be
attributable to the formation of the adduct, which
might interfere with the conversion of protofibrils
to fibrils. To address this hypothesis, monomeric
α-synuclein that had been modified by unlabeled
dopamine was purified and mixed in various pro-
portions with unmodified monomer. The mixtures
were then incubated at 37°C, and the formation of
fibrils and protofibrils was monitored by the
thioflavin-T fluorescence assay and by gel filtration,
respectively. Fibrillization occurred less rapidly,
whereas protofibrils accumulated to a greater
extent and for a longer time in mixtures that con-
tained higher amounts of dopamine–α-synuclein
adduct. From these results, we concluded that the
dopamine–α-synuclein adduct slows the conversion
of protofibrils to fibrils. As one possibility, this inhi-
bition might be attributable to an unfavorable inter-
action between the dopamine–α-synuclein adduct
and the unmodified protein.
A Yeast Model to Isolate Random
α-Synuclein Mutants
As part of our ongoing effort to validate the toxic
protofibril hypothesis in vivo, we established a yeast
model to identify random mutants with varying
propensities to aggregate. Our goal at the outset was
to identify α-synuclein variants that readily form
protofibrils but do not convert to fibrils. If the hypoth-
esis were correct, then transgenic animals that pro-
duced high levels of such mutants should develop
a more severe Parkinsonian phenotype.
Our yeast model was designed so that the extent
of α-synuclein aggregation would be reflected by a
macroscopic property of the yeast, using an approach
similar to that used to study the yeast prion protein
Sup35 (Chernoff et al., 2002). Sup35 is a translation
termination factor that consists of amino (N)-, middle
(M)-, and carboxy (C)-terminal domains. If Sup35
is soluble and abundant, then it interacts via
its C-domain with a second subunit, Sup45, to
terminate translation at a stop codon. However, if
Sup35 is aggregated via interactions involving its
Fig. 3. Catechol hydroxyl moieties are essential for the
inhibition of α-synuclein fibrillization by catecholamines.
(A) Structures of fibrillization inhibitors, including dopamine
(1), L-DOPA (2), norepinephrine (3), and epinephrine (4).
(B) Structure of noninhibitors, including 3-methoxy-4-
hydroxyphenethylamine (5), albuterol (6), normetanephrine
(7), and phenylephrine (8).
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N-terminal prion domain, then it can no longer asso-
ciate productively with Sup45, and translation ter-
mination is partially suppressed. The normal and
suppressed translation termination phenotypes are
conveniently distinguished in yeast cells that contain
a nonsense mutation in the ade1-14 gene, which
encodes an enzyme of the adenine biosynthesis path-
way. Yeast cells in which translation termination
occurs normally (referred to as [psi–]) produce a trun-
cated, nonfunctional version of the adenine biosyn-
thetic enzyme, and they are therefore not able to grow
in the absence of adenine. In contrast, yeast cells in
which translation termination is partially suppressed
(referred to as [PSI+]) produce the full-length biosyn-
thetic enzyme and are able to grow in the absence of
adenine.
Using a similar screen, we examined whether trans-
lation termination was suppressed in yeast that
produce a fusion protein in which the N-domain of
Sup35 is replaced by α-synuclein. Our initial goal was
to compare the growth phenotypes of yeast strains
in which the endogenous Sup35 gene was replaced
with DNA encoding WT α-synuclein-, A53T-,
or A30P-Sup35MC. However, we were unable to iso-
late yeast in which the Sup35 gene was substituted
with DNA encoding WT α-synuclein- or A53T-
Sup35MC, suggesting that these two fusion proteins
failed to carry out the translation termination func-
tion of full-length Sup35 (Outeiro et al., unpublished
observations). As an alternate strategy, each α-synu-
clein-Sup35MC DNA was expressed in [psi–] yeast
that contained the endogenous Sup35 gene. We
found that translation termination was partially
suppressed in yeast that produced WT α-synuclein-
or A53T-Sup35MC, but not A30P-Sup35MC (Fig. 5A).
Subsequently, we observed that yeast producing
β-synuclein-Sup35MC, but not γ-synuclein- or
[A30P+A53T]-Sup35MC, exhibited a partially sup-
pressed translation-termination phenotype. Impor-
tantly, synuclein variants that caused suppression
when fused to Sup35MC are reported to have a rel-
atively high affinity for lipid membranes, whereas
the synuclein variants that did not interfere with
translation termination when fused to Sup35MC
have a low affinity for membranes (Jensen et al., 1998;
Perrin et al., 2000; Cole et al., 2002; Jo et al., 2002). In
contrast, some forms of synuclein that caused sup-
pression when fused to Sup35MC (e.g., β-synuclein)
aggregate poorly in vitro (Giasson et al., 2001),
whereas other forms of synuclein that did not cause
Fig. 4. Treatment of α-synuclein with dopamine leads to the formation of a covalent adduct and the accumulation of
oligomers. (A) Western blot analysis of A53T (1 mM) incubated with dopamine (2 mM) at 37°C. (Lanes 1–9) Analysis of
samples incubated for the indicated times; (lanes 10–13) analysis of fractions recovered after gel filtration of A53T incu-
bated with dopamine for 11 d. (Fraction a) Void-volume oligomer; (fraction b) included-volume oligomer; (fraction c)
dimer; (fraction d) monomer. SDS-PAGE was carried out with a 10–20% polyacrylamide, tricine gel. The primary anti-
body was Syn-1 (Transduction Labs). (B) Gel-filtration chromatogram of A53T (1 mM) treated with [2,5,6-3H]dopamine
(2 mM, 5 mCi/mmol), monitored by scintillation counting (top) and A276 (bottom). The solution was analyzed immedi-
ately (left) or after incubation for 11 d at 37°C (right). Oligomers eluted between 15 and 22 min, a dimer of α-synuclein
eluted between 22 and 24 min, and the monomer eluted between 25 and 30 min.
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suppression (e.g., the [A30P+A53T] mutant) aggre-
gate efficiently in the test tube. When produced as
fusions, with green fluorescent protein (GFP) vari-
ants of synuclein that had caused suppression (when
fused to Sup35MC) were found to localize to the
plasma membrane or form a punctate pattern of flu-
orescence (perhaps because of association with
organelles and/or vesicles) (Fig. 5B) (Outeiro and
Lindquist, 2003). Conversely, the forms of synuclein
that did not interfere with translation termination
produced a diffuse pattern of fluorescence when
fused to GFP (Fig. 5B). Finally, attempts to isolate α-
synuclein-Sup35MC aggregates specifically from
partially suppressed yeast, using ultracentrifuga-
tion protocols that have been shown to pellet aggre-
gated Sup35 from [PSI+] yeast (Chernoff et al., 2002),
were unsuccessful.
From all of this evidence, we infer that the
α-synuclein-Sup35MC fusions that cause suppres-
sion in [psi–] yeast might do so by binding to cellu-
lar membranes. As one possible mechanism,
membrane binding by α-synuclein-Sup35MC might
lead to the mislocalization of Sup45 to the mem-
brane, because of the interaction between Sup45 and
the Sup35C-domain of the fusion protein. In turn,
this mislocalization would be expected to interfere
with translation termination by endogenous Sup35.
The results of preliminary experiments, which sug-
gest that excess Sup45 partially rescues suppression
from α-synuclein-Sup35MC, provide some sup-
porting evidence for this mechanism (not shown).
Importantly, the results imply that we have gener-
ated a yeast model for which the growth of colonies
reflects the binding of α-synuclein to cellular mem-
branes—not the aggregation of the protein, as
observed in the test tube. Although this model dif-
fers from that which was anticipated at the start of
this project, it will nevertheless be invaluable to stud-
ies that address how α-synuclein membrane interac-
tions play a role in the pathogenesis of PD (see below).
Discussion
We have shown that α-synuclein protofibrils are
enriched with β-sheet and exist as individual spheres,
elongated chains, or rings. In contrast to the
monomer or fibril, protofibrils bind and perme-
abilize lipid vesicles, perhaps via a pore-like
mechanism similar to β-sheet-rich, membrane-
permeabilizing toxins (Volles et al., 2001; Ding et al.,
2002). Under oxidizing conditions, α-synuclein
reacts with dopamine (possibly in its quinone form)
to yield a covalent adduct that promotes the accu-
mulation of protofibrils. Our results suggest the fol-
lowing model to explain the susceptibility of
dopaminergic neurons in PD (Fig. 6). After a suffi-
ciently long lag time, corresponding to years in a
patient prior to disease onset, α-synuclein might
form protofibrils via a nucleation-dependent mech-
anism. The protofibrils might be toxic because of
Fig. 5. α-Synuclein variants have different propensities to bind membranes in a yeast model. (A) [psi–] ade1-14 yeast
cells that produce WT α-synuclein or A53T fused to Sup35MC (WT-MC or A53T-MC, respectively) have a partially sup-
pressed translation termination phenotype. In contrast, [psi–] ade1-14 yeast cells that contain the control vector (Vector)
or produce A30P fused to Sup35MC (A30P-MC) have a normal translation termination phenotype. Yeast cells were plated
on synthetic media lacking uracil (to select for yeast carrying expression constructs with a Ura marker) and adenine (to
select for yeast with a partially suppressed translation termination phenotype). Translation termination is partially sup-
pressed in yeast cells that produce α-synuclein variants with high membrane-binding affinities. (B) Green fluorescent
protein (GFP) fluorescence is punctate in yeast cells that produce WT α-synuclein or A53T fused to GFP (WT or A53T,
respectively), whereas it is diffuse in yeast cells that produce unfused GFP (GFP) or A30P fused to GFP (A30P). Punctate
fluorescence might reflect the binding of α-synuclein to organellar or vesicular membranes.
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their ability to permeabilize membranes, which in
turn might lead to the inappropriate redistribution
of vesicular or organellar contents (see below). The
accumulation of toxic protofibrils might be favored
by the intracellular conditions expected of a dopa-
minergic neuron, namely, oxidative stress and the
presence of cytosolic dopamine. Under these
conditions, dopamine and α-synuclein might react
to form an adduct that slows the conversion of
protofibrils to less toxic fibrils. However, in non-
dopaminergic neurons with relatively low levels
of oxidative stress or cytosolic dopamine, the
dopamine–α-synuclein adduct is not expected to be
formed readily. In this case, toxic protofibrils would
be rapidly consumed by fibrillization, and, there-
fore, the neurons should be relatively spared.
This model predicts that the presence of high levels
of cytosolic dopamine is critical to the selective
degeneration of dopaminergic neurons in PD. Con-
sistent with this prediction, dopaminergic neurons
of the substantia nigra are more vulnerable than
those of the ventral tegmental area, in which higher
levels of vesicular monoamine transporter (VMAT2)
efficiently sequester dopamine out of the cytosol and
into synaptic vesicles. In addition, protofibrillar α-
synuclein might trigger a vicious cycle by perme-
abilizing dopamine-containing vesicles, which
would lead to further increases in the levels of cyto-
plasmic dopamine and dopamine– α-synuclein
adduct. In support of this mechanism, the produc-
tion of α-synuclein in differentiated mesencephalic
neurons leads to increased levels of dopamine in the
cytosol (Lotharius et al., 2002). Our model also
addresses the question of why age is a risk factor in
sporadic PD: Not only does the nucleation of
protofibrils occur only after a sufficient lag time, but
the oxidizing conditions of dopaminergic neurons
that lead to protofibril stabilization also become more
pronounced with age. Finally, the fact that the two
α-synuclein mutants, A53T and A30P, form
potentially toxic protofibrils more rapidly than WT
α-synuclein might account for these mutants being
associated with an early-onset form of the disease.
Acurrent goal is to achieve a more complete under-
standing of how α-synuclein protofibrils are linked
to pathogenesis in PD. As one approach, we have
begun to identify which species among the total
population of protofibrils have the highest levels of
specific membrane-permeabilizing activity. Once
purified, the structure-function relationships of these
species can be elucidated in greater detail. We are
also conducting experiments to identify the site(s)
on α-synuclein that react with dopamine to form the
covalent adduct. Once the targeted residues are iden-
tified, it might be possible to test the importance of
the dopamine–α-synuclein adduct in vivo using
mutants in which the modification sites are disrupted.
We also aim to develop a screen for compounds that
inhibit the formation of the dopamine–α-synuclein
adduct in dopaminergic neurons. To this end, we
Fig. 6. The degeneration of dopaminergic neurons in PD might result from the aggregation and oxidation of α-synuclein,
leading to membrane permeabilization. The conversion of natively unfolded, monomeric α-synuclein (left) to protofibrils
(middle) is an unfavorable process (longer arrow in the reverse direction) that only occurs after an extended lag phase. The
protofibrils might form toxic, pore-like structures (upper right) that permeabilize vesicles or organelles. Alternatively,
α-synuclein protofibrils might assemble to form potentially less toxic fibrils (lower right). The highly oxidizing conditions
in the cytosol of dopaminergic neurons might favor the formation of a dopamine–α-synuclein adduct, which promotes the
accumulation of toxic protofibrils by inhibiting their conversion to fibrils. Therefore, this model provides a possible expla-
nation for dopaminergic neurons being highly susceptible to the toxic effects of α-synuclein.
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have begun to develop a protocol to monitor forma-
tion of the adduct in SH-SY5Y and PC12 cells.
In addition to studies of the structure and
function of α-synuclein protofibrils in the test tube,
experiments were conducted to assess the effects
of producing α-synuclein in yeast. Initially, the
goal was to develop a genetically tractable model
that would facilitate the identification of random
α-synuclein mutants with different propensities to
aggregate. However, our findings from analyses of
yeast cells that produce α-synuclein-Sup35MC sug-
gest that this model might provide a macroscopic
readout for the binding of intracellular mem-
branes by α-synuclein, rather than the formation of
α-synuclein protofibrils or fibrils. Nevertheless, this
model might still be a useful tool in addressing an
important question in the field of PD research:
namely, does α-synuclein form toxic aggregates
when bound to cellular membranes or when free in
the cytosol? Results of experiments in isolated brain
fractions and mammalian cells suggest that the bind-
ing of monomeric α-synuclein to intracellular mem-
branes might be an initiating event that leads to the
formation of toxic aggregates (Lee et al., 2002). To
address this hypothesis, we propose that our yeast
model could be used to identify random α-synuclein
mutants with different membrane-binding affini-
ties. In turn, these mutants could be tested for
their effects on the Parkinsonian phenotype of
α-synuclein-transgenic mice or flies. The results of
these studies would provide insight into whether
membrane binding by monomeric α-synuclein is
necessary to trigger neurodegeneration. Clearly, this
information is critical for the optimal design of
screens to identify drugs that block the toxic effects
of α-synuclein in PD.
Acknowledgments
This work was supported by an NINDS Morris
K. Udall Parkinson’s Disease Research Center of
Excellence grant (NS38375), the NIA (AG14366 and
AG08470), the Alzheimer ’s Association Zenith
Fellows Award, the James K. Warsaw Foundation
to Cure Parkinson’s Disease, and the Kinetics
Foundation. J.- C. R. received postdoctoral fellow-
ships from the Alberta Heritage Foundation for
Medical Research and the Human Frontiers Science
Program. T. F. O. was sponsored by BD18489/98 from
the Fundação para Ciência e Tecnologia, Portugal.
M. J. V. received a predoctoral fellowship from the
National Science Foundation.
References
Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S.,
Nakamura M., et al. (1998) NACP/α-synuclein
immunoreactivity in fibrillary components of neuronal
and oligodendroglial cytoplasmic inclusions in the pon-
tine nuclei in multiple system atrophy. Acta Neuropathol.
(Berl.) 96, 439–444.
Baba M., Nakajo S., Tu P.- H., Tomita T., Nakaya K., Lee
V. M.- Y., et al. (1998) Aggregation of α-synuclein in
Lewy bodies of sporadic Parkinson’s disease and
dementia with Lewy bodies. Am. J. Pathol. 152, 879–884.
Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M.,
Panov A. V., and Greenamyre J. T. (2000) Chronic
systemic pesticide exposure reproduces features of
Parkinson’s disease. Nat. Neurosci. 3, 1301–1306.
Bussell R. and Eliezer D. (2003) Astructural and functional
role for 11-mer repeats in α-synuclein and other
exchangeable lipid binding proteins. J. Mol. Biol. 329,
763–778.
Chandra S., Chen X., Rizo J., Jahn R., and Sudhof T. C.
(2003) A broken α-helix in folded α-synuclein. J. Biol.
Chem. 278, 15313–15318.
Chernoff Y. O., Uptain S. M., and Lindquist S. L. (2002) Analy-
sis of prion factors in yeast. Methods Enzymol.351,499–538.
Clayton D. F. and George J. M. (1999) Synucleins in
synaptic plasticity and neurodegenerative disorders.
J. Neurosci. Res. 58, 120–129.
Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle
D., and Nussbaum R. L. (2002) Lipid droplet binding
and oligomerization properties of the Parkinson’s dis-
ease protein α-synuclein. J. Biol. Chem. 277, 6344–6352.
Conway K. A., Harper J. D., and Lansbury P. T. (1998)
Accelerated in vitro fibril formation by a mutant
α-synuclein linked to early-onset Parkinson disease.
Nat. Med. 4, 1318–1320.
Conway K. A., Harper J. D., and Lansbury P. T., Jr. (2000)
Fibrils formed in vitro from α-synuclein and two mutant
forms linked to Parkinson’s disease are typical amy-
loid. Biochemistry 39, 2552–2563.
Conway K. A., Rochet J.-C., Bieganski R. M., and
Lansbury P. T., Jr. (2001) Kinetic stabilization of the
α-synuclein protofibril by a dopamine-α-synuclein
adduct. Science 294, 1346–1349.
Davidson W. S., Jonas A., Clayton D. F., and George J. M.
(1998) Stabilization of α-synuclein secondary structure
upon binding to synthetic membranes. J. Biol. Chem.
273, 9443–9449.
Dawson T. M. and Dawson V. L. (2002) Neuroprotective
and neurorestorative strategies for Parkinson’s disease.
Nat. Neurosci. Suppl. 5, 1058–1061.
Ding T. T., Lee S.- J., Rochet J.- C , and Lansbury P. T., Jr.
(2002) Annular α-synuclein protofibrils are produced
when spherical protofibrils are incubated in solution
or bound to brain-derived membranes. Biochemistry 41,
10209–10217.
Dunnett S. B. and Bjorklund A. (1999) Prospects for new
restorative and neuroprotective treatments in Parkin-
son’s disease. Nature (Suppl.)399, A32–A39.
32 Rochet et al.
Journal of Molecular Neuroscience Volume 23, 2004
El-Agnaf O. M., Jakes R., Curran M. D , and Wallace A.
(1998) Effects of the mutations Ala30 to Pro and Ala53
to Thr on the physical and morphological properties
of α-synuclein protein implicated in Parkinson’s dis-
ease. FEBS Lett. 440, 67–70.
Eliezer D., Kutluay E., Bussell R., Jr., and Browne G. (2001)
Conformational properties of α-synuclein in its free
and lipid-associated states. J. Mol. Biol. 307, 1061–1073.
Feany M. B. and Bender W. W. (2000) A Drosophila model
of Parkinson’s disease. Nature 404, 394–398.
Forno L. S. (1996) Neuropathology of Parkinson’s disease.
J. Neuropathol. Exp. Neurol. 55, 259–272.
Giasson B. I., Murray I. V., Trojanowski J. Q., and Lee
V. M. (2001) A hydrophobic stretch of 12 amino acid
residues in the middle of α-synuclein is essential for
filament assembly. J. Biol. Chem. 276, 2380–2386.
Giasson B. I., Uryu K., Trojanowski J. Q., and Lee V. M.-Y.
(1999) Mutant and wild type human α-synucleins
assemble into elongated filaments with distinct mor-
phologies in vitro. J. Biol. Chem. 274, 7619–7622.
Harper J. D., Lieber C. M., and Lansbury P. T., Jr. (1997a)
Atomic force microscopic imaging of seeded fibril for-
mation and fibril branching by the Alzheimer’s disease
amyloid-β-protein. Chem. Biol. 4, 951–959.
Harper J. D., Wong S. S., Lieber C. M., and Lansbury P. T.,
Jr. (1997b) Observation of metastable Aβ amyloid
protofibrils by atomic force microscopy. Chem. Biol. 4,
119–125.
Hashimoto M., Hsu L. J., Sisk A., Xia Y., Takeda A.,
Sundsmo M., and Masliah E. (1998) Human recombi-
nant NACP/α-synuclein is aggregated and fibrillated
in vitro: relevance for Lewy body disease. Brain Res.
799, 301–306.
Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L.,
de Silva, H. A., et al. (1995) The precursor protein of
non-A beta component of Alzheimer’s disease amy-
loid is a presynaptic protein of the central nervous
system. Neuron 14, 467–475.
Jakes R., Spillantini M. G., and Goedert M. (1994) Identi-
fication of two distinct synucleins from human brain.
FEBS Lett. 345, 27–32.
Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G., and Goed-
ert M. (1998) Binding of α-synuclein to brain vesicles
is abolished by familial Parkinson’s disease mutation.
J. Biol. Chem. 273, 26292–26294.
Jo E., Fuller N., Rand R. P., St. George-Hyslop P., and Fraser
P. E. (2002) Defective membrane interactions of famil-
ial Parkinson’s disease mutant A30P α-synuclein.
J. Mol. Biol. 315, 799–807.
Jo E., McLaurin J., Yip C. M., St. George-Hyslop P., and
Fraser P. E. (2000) α-Synuclein membrane interactions
and lipid specificity. J. Biol. Chem. 275, 34328–34334.
Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen
T. E., Muzyczka N., et al. (2002) Parkinson-like
neurodegeneration induced by targeted overexpression
of α-synuclein in the nigrostriatal system. J. Neurosci.
22, 2780–2791.
Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M.,
Kosel S., et al. (1998) Ala30Pro mutation in the gene
encoding α-synuclein in Parkinson’s disease. Nat.
Genet. 18, 106–108.
Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak
R. J., Walz T., and Lansbury P. T., Jr. (2002) α-Synuclein,
especially the Parkinson’s disease-associated mutants,
forms pore-like annular and tubular protofibrils. J. Mol.
Biol. 322, 1089–1102.
Lee H.- J., Choi C., and Lee S.- J. (2002) Membrane-bound
α-synuclein has a high aggregation propensity and the
ability to seed the aggregation of the cytosolic form.
J. Biol. Chem. 277, 671–678.
Li J., Uversky V. N., and Fink A. L. (2001) Effect of famil-
ial Parkinson’s disease point mutations A30P and
A53T on the structural properties, aggregation, and
fibrillation of human α-synuclein. Biochemistry 40,
11604–11613.
Li J., Uversky V. N., and Fink A. L. (2002) Conformational
behavior of human α-synuclein is modulated by famil-
ial Parkinson’s disease point mutations A30Pand A53T.
Neurotoxicology 23, 553–567.
Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K.,
and Brundin P. (2002) Effect of mutant α-synuclein on
dopamine homeostasis in a new human mesencephalic
cell line. J. Biol. Chem. 277, 38884–38894.
Maroteaux L., Campanelli J. T., and Scheller R. H. (1988)
Synuclein: a neuron-specific protein localized to the
nucleus and presynaptic nerve terminal. J. Neurosci. 8,
2804–2815.
Masliah E., Rockenstein E., Veinbergs I., Mallory M.,
Hashimoto M., Takeda A., et al. (2000) Dopaminergic
loss and inclusion body formation in α-synuclein mice:
implications for neurodegenerative disorders. Science
287, 1265–1269.
Narhi L., Wood S. J., Steavenson S., Jiang Y., Wu G. M.,
Anafi D., et al. (1999) Both familial Parkinson’s disease
mutations accelerate α-synuclein aggregation. J. Biol.
Chem. 274, 9843–9846.
Orth M. and Schapira A. H. (2002) Mitochondrial involve-
ment in Parkinson’s disease. Neurochem. Int. 40, 533–541.
Outeiro T. F., Lindquist S. (2003) Yeast cells provide insight
into α-synuclein biology and pathobiology. Science 302,
1772–1775.
Perrin R. J., Woods W. S., Clayton D. F., and George J. M.
(2000) Interaction of human α-synuclein and Parkin-
son’s disease variants with phospholipids. Structural
analysis using site-directed mutagenesis. J. Biol. Chem.
275, 34393–34398.
Pollanen M. S., Dickson D. W., and Bergeron C. (1993)
Pathology and biology of the Lewy body. J. Neuropath.
Exp. Neurol. 52, 183–191.
Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E.,
Dehejia A., Dutra A., et al. (1997) Mutation in the
α-synuclein gene identified in families with Parkin-
son’s disease. Science 276, 2045–2047.
Sherer T. B., Betarbet R., and Greenamyre J. T. (2002)
Environment, mitochondria, and Parkinson’s disease.
Neuroscientist 8, 192–197.
Sherer T. B., Kim J. H., Betarbet R., and Greenamyre J. T.
(2003) Subcutaneous rotenone exposure causes highly
α-Synuclein, Dopamine, and Membranes 33
Journal of Molecular Neuroscience Volume 23, 2004
selective dopaminergic degeneration and α-synuclein
aggregation. Exp. Neurol. 179, 9–16.
Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M.,
and Goedert M. (1998) α-Synuclein in filamentous
inclusions of Lewy bodies from Parkinson’s disease
and dementia with Lewy bodies. Proc. Natl. Acad. Sci.
USA 95, 6469–6473.
Spillantini M. G., Schmidt M. L., Lee V. M.- Y., Trojanowski
J. Q., Jakes R., and Goedert M. (1997) α-Synuclein in
Lewy bodies. Nature 388, 839–840.
Takahashi H. and Wakabayashi K. (2001). The cellular
pathology of Parkinson’s disease. Neuropathology 21,
315–322.
Tompkins M. M. and Hill W. D. (1997) Contribution of
somal Lewy bodies to neuronal death. Brain Res. 775,
24–29.
van Duinen S. G., Lammers G. J., Maat-Schieman
M. L., and Roos R. A. (1999) Numerous and wide-
spread α-synuclein-negative Lewy bodies in an
asymptomatic patient. Acta Neuropathol. (Berl.) 97,
533–539.
Volles M. J., Lee S.- J., Rochet J.- C., Shtilerman M. D., Ding
T. T., Kessler J. C., and Lansbury P. T., Jr. (2001) Vesicle
permeabilization by protofibrillar α-synuclein: impli-
cations for the pathogenesis and treatment of Parkin-
son’s disease. Biochemistry 40, 7812–7819.
Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto
M., and Takahashi H. (1997) NACP, a presynaptic pro-
tein, immunoreactivity in Lewy bodies in Parkinson’s
disease. Neurosci. Lett. 239, 45–48.
Walsh D. M., Lomakin A., Benedek G. B., Condron M. M.,
and Teplow D. B. (1997) Amyloid beta-protein fibril-
logenesis. Detection of a protofibrillar intermediate.
J. Biol. Chem. 272, 22364–22372.
Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and
Lansbury P. T., Jr. (1996) NACP, a protein implicated in
Alzheimer’s disease and learning, is natively unfolded.
Biochemistry 35, 13709–13715.
